- Home
- XNCR vs ORGO Comparison
XNCR vs ORGO Comparison
Compare XNCR & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNCR
- ORGO
- Stock Information
- Founded
- XNCR 1997
- ORGO 1985
- Country
- XNCR United States
- ORGO United States
- Employees
- XNCR N/A
- ORGO N/A
- Industry
- XNCR Biotechnology: Pharmaceutical Preparations
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- XNCR Health Care
- ORGO Health Care
- Exchange
- XNCR Nasdaq
- ORGO Nasdaq
- Market Cap
- XNCR 547.8M
- ORGO 620.3M
- IPO Year
- XNCR 2013
- ORGO N/A
- Fundamental
- Price
- XNCR $13.61
- ORGO $3.96
- Analyst Decision
- XNCR Buy
- ORGO Buy
- Analyst Count
- XNCR 11
- ORGO 3
- Target Price
- XNCR $22.20
- ORGO $7.33
- AVG Volume (30 Days)
- XNCR 1.3M
- ORGO 801.0K
- Earning Date
- XNCR 11-05-2025
- ORGO 11-06-2025
- Dividend Yield
- XNCR N/A
- ORGO N/A
- EPS Growth
- XNCR N/A
- ORGO N/A
- EPS
- XNCR N/A
- ORGO N/A
- Revenue
- XNCR $146,929,000.00
- ORGO $429,531,000.00
- Revenue This Year
- XNCR $23.31
- ORGO $2.51
- Revenue Next Year
- XNCR N/A
- ORGO $25.45
- P/E Ratio
- XNCR N/A
- ORGO N/A
- Revenue Growth
- XNCR N/A
- ORGO N/A
- 52 Week Low
- XNCR $6.92
- ORGO $2.61
- 52 Week High
- XNCR $27.24
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- XNCR 88.43
- ORGO 35.65
- Support Level
- XNCR $11.36
- ORGO $3.90
- Resistance Level
- XNCR $13.07
- ORGO $4.40
- Average True Range (ATR)
- XNCR 0.63
- ORGO 0.23
- MACD
- XNCR 0.16
- ORGO -0.05
- Stochastic Oscillator
- XNCR 94.92
- ORGO 5.53
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.